Influenza virus-like particle vaccines (Q37434529)

20 August 2017

1 reference

title

Influenza virus-like particle vaccines (English)

1 reference

20 August 2017

0 references

Joel R Haynes

1

1 reference

20 August 2017

1 April 2009

1 reference

Expert Review of Vaccines

20 August 2017

1 reference

20 August 2017

8

1 reference

20 August 2017

435-445

1 reference

20 August 2017

4

1 reference

Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity

20 August 2017

1 reference

A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure.

21 January 2018

1 reference

Protection against filovirus infection: virus-like particle vaccines

21 January 2018

1 reference

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

21 January 2018

1 reference

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates

21 January 2018

1 reference

A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.

21 January 2018

1 reference

Impact of the human papilloma vaccine on cervical cancer

21 January 2018

1 reference

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

21 January 2018

1 reference

Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

21 January 2018

1 reference

Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles

21 January 2018

1 reference

The virosome concept for influenza vaccines

21 January 2018

1 reference

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations

21 January 2018

1 reference

Influenza viruses select ordered lipid domains during budding from the plasma membrane

21 January 2018

1 reference

Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins

21 January 2018

1 reference

Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion

21 January 2018

1 reference

Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses

21 January 2018

1 reference

Influenza virus assembly and budding at the viral budozone.

21 January 2018

1 reference

Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein

21 January 2018

1 reference

Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins

21 January 2018

1 reference

Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape

21 January 2018

1 reference

The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging

21 January 2018

1 reference

Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production

21 January 2018

1 reference

The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding

21 January 2018

1 reference

Influenza virus matrix protein is the major driving force in virus budding.

21 January 2018

1 reference

21 January 2018

1 reference

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

21 January 2018

1 reference

HIV-1 gag proteins: diverse functions in the virus life cycle

21 January 2018

1 reference

A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding

21 January 2018

1 reference

Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4.

21 January 2018

1 reference

Vesicular release of ebola virus matrix protein VP40.

21 January 2018

1 reference

Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles

21 January 2018

1 reference

Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization

21 January 2018

1 reference

Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus

21 January 2018

1 reference

Requirements for budding of paramyxovirus simian virus 5 virus-like particles.

21 January 2018

1 reference

Paramyxovirus Sendai virus-like particle formation by expression of multiple viral proteins and acceleration of its release by C protein

21 January 2018

1 reference

Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles

21 January 2018

1 reference

Plasmid-driven formation of influenza virus-like particles

21 January 2018

1 reference

Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles

21 January 2018

1 reference

Generation of influenza A viruses entirely from cloned cDNAs

21 January 2018

1 reference

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

21 January 2018

1 reference

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

21 January 2018

1 reference

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

21 January 2018

1 reference

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

21 January 2018

1 reference

A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).

21 January 2018

1 reference

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

21 January 2018

1 reference

Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly.

21 January 2018

1 reference

Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts

21 January 2018

1 reference

Lipid rafts and pseudotyping.

21 January 2018

1 reference

Do lipid rafts mediate virus assembly and pseudotyping?

21 January 2018

1 reference

Lipid rafts: bringing order to chaos

21 January 2018

1 reference

Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain

21 January 2018

1 reference

Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding

21 January 2018

1 reference

HIV-1 assembly: viral glycoproteins segregate quantally to lipid rafts that associate individually with HIV-1 capsids and virions

21 January 2018

1 reference

In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding.

21 January 2018

1 reference

Pathogens: raft hijackers

21 January 2018

1 reference

Cellular proteins in influenza virus particles

21 January 2018

1 reference

Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses

21 January 2018

1 reference

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge

21 January 2018

1 reference

Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector

21 January 2018

1 reference

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

21 January 2018

1 reference

Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus

21 January 2018

1 reference

Caveolin-1 interacts with the Gag precursor of murine leukaemia virus and modulates virus production.

21 January 2018

1 reference

Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors

21 January 2018

1 reference

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

21 January 2018

1 reference

Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge

21 January 2018

1 reference

Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza

21 January 2018

1 reference

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs

21 January 2018

1 reference

Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

21 January 2018

1 reference

Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients

21 January 2018

1 reference

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

21 January 2018

1 reference

Universal influenza A vaccine: optimization of M2-based constructs.

21 January 2018

1 reference

A "universal" human influenza A vaccine

21 January 2018

1 reference

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

21 January 2018

1 reference

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

21 January 2018

1 reference

Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus

21 January 2018

1 reference

The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.8

1 reference

20 August 2017

1 reference

PubMed ID

19348559